GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Univo Pharmaceuticals Ltd (XTAE:UNVO-M) » Definitions » EBIT

Univo Pharmaceuticals (XTAE:UNVO-M) EBIT : ₪-29.00 Mil (TTM As of Jun. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Univo Pharmaceuticals EBIT?

Univo Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2022 was ₪-20.90 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2022 was ₪-29.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Univo Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2022 was -127.34%. Univo Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -155.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Univo Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -71.92%.


Univo Pharmaceuticals EBIT Historical Data

The historical data trend for Univo Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Univo Pharmaceuticals EBIT Chart

Univo Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBIT
Get a 7-Day Free Trial Premium Member Only -0.49 -56.62 -11.39 0.01 -0.67

Univo Pharmaceuticals Quarterly Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.74 -1.50 -4.23 -2.37 -20.90

Competitive Comparison of Univo Pharmaceuticals's EBIT

For the Biotechnology subindustry, Univo Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Univo Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Univo Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Univo Pharmaceuticals's EV-to-EBIT falls into.


;
;

Univo Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-29.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Univo Pharmaceuticals  (XTAE:UNVO-M) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Univo Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2022 is calculated as:

ROC % (Q: Jun. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2022 ) + Invested Capital (Q: Jun. 2022 ))/ count )
=-83.756 * ( 1 - -2.25% )/( (76.523 + 57.981)/ 2 )
=-85.64051/67.252
=-127.34 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Univo Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2022  Q: Jun. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-83.604/( ( (37.338 + max(22.106, 0)) + (34.351 + max(13.589, 0)) )/ 2 )
=-83.604/( ( 59.444 + 47.94 )/ 2 )
=-83.604/53.692
=-155.71 %

where Working Capital is:

Working Capital(Q: Mar. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.318 + 27.969 + 0.97499999999999) - (14.156 + 0 + 0)
=22.106

Working Capital(Q: Jun. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.602 + 17.559 + 0.882) - (13.454 + 0 + 0)
=13.589

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Univo Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2022 )
=-28.998/40.322
=-71.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Univo Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Univo Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Univo Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Harshar 20, Ashkelon, ISR, 7878329
Univo Pharmaceuticals Ltd is engaged in designing & developing drugs for the treatment of brain disorders. The company provides cannabis-based products for distribution and export to the international markets.

Univo Pharmaceuticals Headlines

No Headlines